These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 19147532)

  • 1. Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?
    Wade M; Wahl GM
    Mol Cancer Res; 2009 Jan; 7(1):1-11. PubMed ID: 19147532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting p53-MDM2-MDMX loop for cancer therapy.
    Zhang Q; Zeng SX; Lu H
    Subcell Biochem; 2014; 85():281-319. PubMed ID: 25201201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mdmx and Mdm2: brothers in arms?
    Marine JC; Jochemsen AG
    Cell Cycle; 2004 Jul; 3(7):900-4. PubMed ID: 15254433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stochastic modeling and simulation of the p53-MDM2/MDMX loop.
    Cai X; Yuan ZM
    J Comput Biol; 2009 Jul; 16(7):917-33. PubMed ID: 19580521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of p53: a collaboration between Mdm2 and Mdmx.
    Pei D; Zhang Y; Zheng J
    Oncotarget; 2012 Mar; 3(3):228-35. PubMed ID: 22410433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mdmx promotes genomic instability independent of p53 and Mdm2.
    Carrillo AM; Bouska A; Arrate MP; Eischen CM
    Oncogene; 2015 Feb; 34(7):846-56. PubMed ID: 24608433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
    Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
    Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. When the guardian sleeps: Reactivation of the p53 pathway in cancer.
    Merkel O; Taylor N; Prutsch N; Staber PB; Moriggl R; Turner SD; Kenner L
    Mutat Res Rev Mutat Res; 2017 Jul; 773():1-13. PubMed ID: 28927521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase.
    Okamoto K; Taya Y; Nakagama H
    FEBS Lett; 2009 Sep; 583(17):2710-4. PubMed ID: 19619542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells.
    Gao C; Xiao G; Piersigilli A; Gou J; Ogunwobi O; Bargonetti J
    Breast Cancer Res; 2019 Jan; 21(1):5. PubMed ID: 30642351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The p53 orchestra: Mdm2 and Mdmx set the tone.
    Wade M; Wang YV; Wahl GM
    Trends Cell Biol; 2010 May; 20(5):299-309. PubMed ID: 20172729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
    Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
    Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel simplified yeast-based assays of regulators of p53-MDMX interaction and p53 transcriptional activity.
    Leão M; Gomes S; Soares J; Bessa C; Maciel C; Ciribilli Y; Pereira C; Inga A; Saraiva L
    FEBS J; 2013 Dec; 280(24):6498-507. PubMed ID: 24119020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations.
    Yu Q; Li Y; Mu K; Li Z; Meng Q; Wu X; Wang Y; Li L
    Diagn Pathol; 2014 Mar; 9():71. PubMed ID: 24667108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches.
    Joerger AC; Fersht AR
    Annu Rev Biochem; 2016 Jun; 85():375-404. PubMed ID: 27145840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [NEGATIVE REGULATORS OF TUMOR SUPPRESSOR P53 IN THE CONTEXT OF ANTICANCER THERAPY].
    Shuvalov OY; Fedorova OA; Petukhov AV; Daks AA; Vasilieva EA; Grigorieva TA; Ivanov GS; Barlev NA
    Tsitologiia; 2015; 57(12):847-54. PubMed ID: 26995961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Study of the molecular mechanisms controlling activity of protein p53 in the development of new strategies in cancer therapeutics].
    Marine Ch
    Bull Mem Acad R Med Belg; 2009; 164(5-6):175-80; discussion 180-1. PubMed ID: 20666148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A site-directed mutagenesis study of the MdmX RING domain.
    Egorova O; Mis M; Sheng Y
    Biochem Biophys Res Commun; 2014 May; 447(4):696-701. PubMed ID: 24755078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
    Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G
    J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination.
    Wang X; Wang J; Jiang X
    J Biol Chem; 2011 Jul; 286(27):23725-34. PubMed ID: 21572037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.